Main Industry
Health Care
Main Product/Service
EECP (Enhanced External Counter Pulsation) is a non-invasive external pressure therapy cardiovascular medical device! It can be used to improve heart failure and treat angina pectoris, serving as a major boon especially for heart disease patients who are unable to undergo cardiac stent placement!
Through synchronized monitoring of the electrocardiogram (ECG/EKG) and computer, and controlled by ECG signals, it sequentially applies pressure to the calves, thighs, and buttocks in coordination with the cardiac diastolic and systolic cycles, thereby promoting the development of coronary collateral circulation. By applying pressure to multiple areas of the lower body, it increases diastolic blood return and reduces the workload of the heart!
The VASOBYPASS MEDICAL TECHNOLOGY CORPORATION EECP device has been approved by the Ministry of Health and Welfare for marketing in Taiwan, and is currently in use by multiple medical centers!
(The content above was translated by AI.)
Through synchronized monitoring of the electrocardiogram (ECG/EKG) and computer, and controlled by ECG signals, it sequentially applies pressure to the calves, thighs, and buttocks in coordination with the cardiac diastolic and systolic cycles, thereby promoting the development of coronary collateral circulation. By applying pressure to multiple areas of the lower body, it increases diastolic blood return and reduces the workload of the heart!
The VASOBYPASS MEDICAL TECHNOLOGY CORPORATION EECP device has been approved by the Ministry of Health and Welfare for marketing in Taiwan, and is currently in use by multiple medical centers!
(The content above was translated by AI.)
Founded Year
2014
Unified Business No.
24622513
Status
Active
Number of Employees
0
Total Paid-in
Capital
12,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
VASOBYPASS MEDICAL TECHNOLOGY CORPORATION (hereinafter referred to as the Company) was established in July 2014, focusing on diastolic perfusion devices (also known as External Counter Pulsation Devices). After three years of continuous research and development, the Company finally launched the first domestically produced Enhanced External Counterpulsation (EECP) device in 2017. Following three years of clinical experience and feedback from physicians, the second-generation model was launched in 2020, which obtained a Class III medical device license. To this day, we continue to focus on the research and development of enhanced external counterpulsation devices, adhering to the concept of "First-Class Quality, Innovative Technology, and Comprehensive Service" to develop high-end, safe medical devices that provide healthcare professionals with diastolic perfusion therapy to improve public health.
The Company has always focused on the research and development innovation of product technology and quality improvement. To ensure our products are safer and more effective, to build greater confidence among our customers, and to comply with relevant regulations, the Company has established a quality system for product design, development, manufacturing, installation, and maintenance in accordance with the requirements of ISO 13485:2016 and the Republic of China Quality Management System (QMS) for medical devices, thereby further enhancing and refining the quality of our products.
(The content above was translated by AI.)
The Company has always focused on the research and development innovation of product technology and quality improvement. To ensure our products are safer and more effective, to build greater confidence among our customers, and to comply with relevant regulations, the Company has established a quality system for product design, development, manufacturing, installation, and maintenance in accordance with the requirements of ISO 13485:2016 and the Republic of China Quality Management System (QMS) for medical devices, thereby further enhancing and refining the quality of our products.
(The content above was translated by AI.)
